2001
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
Burstein H, Kuter I, Campos S, Gelman R, Tribou L, Parker L, Manola J, Younger J, Matulonis U, Bunnell C, Partridge A, Richardson P, Clarke K, Shulman L, Winer E. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. Journal Of Clinical Oncology 2001, 19: 2722-30. PMID: 11352965, DOI: 10.1200/jco.2001.19.10.2722.Peer-Reviewed Original ResearchConceptsGrade 2 cardiac toxicityAdvanced breast cancerBreast cancerResponse rateCardiac toxicityHER2-overexpressing metastatic breast cancerOnly grade 4 toxicityHER2-positive breast cancerCumulative doxorubicin doseGrade 4 toxicityStudy of trastuzumabSymptomatic heart failureThird-line therapyFirst-line therapyType of chemotherapyMetastatic breast cancerPercent of womenHigh response rateConcurrent trastuzumabPrior chemotherapyWeekly vinorelbineMetastatic diseasePositive patientsHeart failureDoxorubicin dose
1999
Phase I study of Doxil and vinorelbine in metastatic breast cancer
Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Annals Of Oncology 1999, 10: 1113-1116. PMID: 10572612, DOI: 10.1023/a:1008323200102.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerM2 days 1Breast cancerDay 1Grade 2 cardiac toxicityPrior anthracycline-based chemotherapyAnthracycline-based chemotherapyPhase II studyFirst treatment cyclePhase I studiesDose escalation schemeFavorable toxicity profilePharmacokinetic studyActive chemotherapeutic agentsHigher doxorubicin concentrationsDoxil administrationVinorelbine administrationSignificant nauseaII studySevere neutropeniaCombination chemotherapyCardiac toxicityCombination therapyEscalation schemeI studies